On August 31, 2026 Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum technology, reported the expansion of its radiopharmaceutical development program to evaluate alpha-emitting and beta-emitting radioisotopes. This expansion is to broaden the capability of the Accum platform, which is designed to facilitate intracellular transport for enhanced payload delivery.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The initiative reflects Defence’s growing strategic focus on radiopharmaceuticals, a rapidly advancing area of precision oncology where the Company believes Accum has significant potential to create novel products and improve existing ones. Accum improves how well radioactive drugs get inside cancer cells, allowing more of the cancer-killing payload to reach its target and destroy the tumor from within. Defence is accelerating the development of its internal radiopharmaceutical program to further evaluate this potential and advance Accum-enabled radio-immunoconjugates candidates toward clinical development.

Defence’s radiopharmaceuticals program will evaluate alpha emitters, such as Actinium-225, for their high-energy, short-range localized cellular damage. Concurrently, the Company will evaluate beta emitters, such as Lutetium-177, for their medium-energy, longer-range penetration profiles, allowing for a comprehensive comparison of how different isotope properties are enhanced by the Accum platform.

The expanded program is designed to generate comparative pharmacology, efficacy and safety data across both isotope classes while further establishing Accum as a versatile intracellular delivery platform for a variety of radioisotope payloads. The ongoing preclinical programs are focused on the Accum platform’s core mechanism to optimize accumulation in target cells and reduce off-target toxicity. By building out the preclinical data, Defence aims to deliver clinical candidates and strengthen the Company’s growing pipeline of proprietary radiopharmaceutical assets.

"By expanding our platform development to evaluate both alpha and beta isotopes as distinct pathways, we can comprehensively analyze the compatibility of Accum with different payload profiles," says Dr. Ryan Simms, Defence’s newly instated Chief Operating Officer and Head of Radiopharmaceuticals Program.

"This parallel development program gives Defence the data required to optimize Accum-enhanced radio-immunoconjugates for diverse candidate selections and to establish Accum as a technology capable of enhancing the next generation of targeted therapies across multiple therapeutic modalities," says Dr. Amie Phinney, President and Chief Executive Officer of Defence Therapeutics.

(Press release, Defence Therapeutics, AUG 31, 2026, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-expands-radiopharmaceutical-development-strategy-with-alpha-and-beta-emitter-programs [SID1234670442])

On August 31, 2026 Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need, reported that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference. Dr. Mor’s prerecorded presentation will be webcast and will be available starting on September 11, 2026 at 7:00 am ET. The link to access the webcast is included below and is also available at the Events section of the Chemomab website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Mor and Dr. Reg Seeto, Chief Executive Officer of Scipher Medicine Corporation (Scipher), will be attending the H.C. Wainwright Conference in New York City in person and will be co-hosting 1×1 investor meetings September 14-16, 2026. On July 8, 2026 Chemomab and Scipher announced a definitive merger agreement, which is expected to close before year-end. Based on its pioneering work in immunology precision medicine, Scipher plans to advance Chemomab’s first-in-class anti-CCL24 antibody nebokitug into a Phase 2 trial in rheumatoid arthritis, a $24 billion market opportunity with substantial unmet need.

Chemomab Presentation at H.C. Wainwright 28th Annual Global Investment Conference
Date: September 11, 2026
Time: Available starting at 7:00 am ET for 90 days
Format: Prerecorded webcast presentation
Webcast Link: View Source

For information on attending the 2026 H.C. Wainwright Global Investment Conference, contact your representative or click here.

(Press release, Chemomab, AUG 31, 2026, View Source [SID1234670441])

On August 31, 2026 BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During the second quarter and subsequent period, we advanced GLIX1 across multiple fronts," stated Philip Serlin, Chief Executive Officer of BioLineRx. "Our Phase 1/2a study in glioblastoma is advancing as planned, with the second cohort in the Phase 1 part now being dosed, and the third cohort expected to commence dosing in September. To date, a little more than four months into the study, we have been very pleased with the drug’s safety and tolerability.

"Also, during the quarter, we were excited to demonstrate the potential of GLIX1 to address unmet needs for GBM as well as ovarian cancer in a number of pre-clinical models. In this regard, we announced new data in a temozolomide-resistant patient-derived xenograft (PDX) GBM in-vivo model, in which GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no effect. These results further support GLIX1’s potential to treat a broad range of patients with GBM. We also generated data showing strong synergy between GLIX1 and PARP inhibitors in an HR-proficient patient-derived ovarian cancer in-vivo model, and based upon these excellent findings, we are planning to add an ovarian cancer arm to the Phase 2a expansion phase of the trial. Together, these developments keep GLIX1 on track in glioblastoma while extending its reach into additional tumor types where new treatment options are desperately needed."

Financial Updates

• With $13.1 million on its balance sheet as of June 30, 2026, BioLineRx is maintaining its cash runway guidance into the first half of 2027.

• On August 27, 2026, the Company entered into definitive agreement for an offering with gross proceeds of $3.75 million, expected to close on or about August 31, 2026.

Development Updates

GLIX1 in GBM

• In July, dosing commenced in the second of five planned cohorts in the Phase 1 dose escalation part of the Phase 1/2a study.

o Three leading cancer centers are enrolling patients in the Phase 1 part of the study: NYU Langone Health, led by Dr. Alexandra Miller; Northwestern University, led by Dr. Roger Stupp and Dr. Ditte Primdahl; and Moffit Cancer Center, led by Dr. Patrick Grogan.

o The Phase 1 part of the trial is expected to recruit up to 30 patients with recurrent and progressive GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy.

o The Phase 2a expansion part of the trial is planned to include various population cohorts, including GBM (newly diagnosed and/or recurrent), as well as additional cancers with/without standard of care (e.g., PARP inhibitors), including an ovarian cancer arm. These cohorts are expected to identify preliminary efficacy, PD assessments and dose optimization data, serving as the basis for rapid and effective advanced clinical development.

• New data demonstrated potent anti-tumor effect of GLIX1 in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model. In the three orthotopic CDX studies, significant tumor growth inhibition and survival benefit were observed following treatment with GLIX1 across all doses tested, with greater benefit at higher dose levels. Most notably, in the subcutaneous PDX model, GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no effect.

• Clinical and pre-clinical data has been accepted for publication at the European Association of Neuro-Oncology (EANO) 2026 Conference and at the Society for Neuro-Oncology (SNO) 2026 Annual Meeting.

GLIX1 in combination with PARPi

• New data demonstrated strong synergy between GLIX1 and PARP inhibitors, reinforcing synthetic lethality between GLIX1 and PARP inhibitors.

o Synergy was demonstrated in a patient-derived xenograft (PDX) in-vivo model of HR-proficient ovarian cancer, where PARP inhibitors have historically had limited efficacy. Results show substantially better efficacy in the combination arm versus the control arm and versus the monotherapy arms, despite using lower doses in the combination arm. Notably, the low-dose GLIX1/olaparib combination tumor reduction was similar to cisplatin, the current chemotherapy benchmark.

• An abstract featuring new GLIX1 data, demonstrating synergy with PARP inhibitors in HR-proficient ovarian cancer, was accepted for publication at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026) in October.

• BioLineRx has initiated discussions with leading PARP inhibitor companies to explore potential development collaborations.

Motixafortide

Pancreatic Ductal Adenocarcinoma (mPDAC)

• Enrollment is continuing in the CheMo4METPANC Phase 2b clinical trial, which is being led by Columbia University, and supported by both Regeneron and BioLineRx. The trial is evaluating motixafortide in combination with the PD-1 inhibitor cemiplimab and standard chemotherapy (gemcitabine and nab-paclitaxel).

o A prespecified interim/futility analysis is planned when 40% of progression-free survival (PFS) events are observed, which the Company continues to anticipate will occur in 2026.

APHEXDA Performance Update

• For the second quarter of 2026, APHEXDA sales were $1.6 million, which provided royalty revenue to the Company of $0.3 million.

Financial Results for the Quarter ended June 30, 2026

• Revenues for the three months ended June 30, 2026 were $0.3 million, similar to the three months ended June 30, 2025.

• Research and development expenses for the three months ended June 30, 2026 were $2.9 million, an increase of $0.6 million, or 26.5%, compared to $2.3 million for the comparable 2025 period. The increase resulted primarily from expenses related to the new GLIX1 project, offset by lower expenses related to motixafortide.

• General and administrative expenses for the three months ended June 30, 2026 were $0.9 million, an increase of $0.7 million, or 313.9%, compared to $0.2 million for the comparable 2025 period. The increase resulted from the reversal of a $0.8 million provision for doubtful accounts in the 2025 period following receipt of an overdue milestone payment from Gloria.

• Non-operating expenses amounted to $0.7 million for the three months ended June 30, 2026, compared to non-operating expenses of $1.9 million for the three months ended June 30, 2025. Non-operating expenses for both periods primarily relates to fair-value adjustments of warrant liabilities on the Company’s balance sheet.

• Net financial expenses for the three months ended June 30, 2026 were $0.1 million compared to net financial income of $0.2 million for the three months ended June 30, 2025. Net financial expenses in 2026 primarily relate to interest paid on loans, partially offset by investment income earned on bank deposits. Net financial income in 2025 primarily relates to investment income earned on bank deposits and gains on foreign currency cash balances due to the strengthening of the NIS during the period, partially offset by interest paid on loans.

• Net loss for the three months ended June 30, 2026 was $4.3 million, compared to $3.9 million for the three months ended June 30, 2025.

• As of June 30, 2026, the Company had cash, cash equivalents, and short-term bank deposits of $13.1 million.

Conference Call and Webcast Information

To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company’s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until September 1, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

(Press release, BioLineRx, AUG 31, 2026, View Source [SID1234670440])

On August 31, 2026 Alligator Bioscience AB ("Alligator Bioscience" or the "Company") reported it has prepared a prospectus (the "Prospectus") relating to the rights issue of units of approximately SEK 125.6 million, which was resolved by the board of directors on 23 July 2026, and approved by the extraordinary general meeting held on 26 August 2026 (the "Rights Issue"). The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Summary

Anyone who is registered as a shareholder in Alligator Bioscience on the record date, 2 September 2026, will receive five (5) unit rights for each existing ordinary share in the Company. One (1) unit right entitles the holder to subscribe for one (1) unit. Each unit consists of two (2) ordinary shares, one (1) warrant series TO 15 and one (1) warrant series TO 16. The warrants series TO 15 and TO 16 are intended to be admitted to trading on Nasdaq Stockholm.
The Rights Issue entails the issuance of a maximum of 3,140,534,240 units, corresponding to 6,281,068,480 ordinary shares, 3,140,534,240 warrants series TO 15 and 3,140,534,240 warrants series TO 16.
The subscription price in the Rights Issue has been set to SEK 0.04 per unit, corresponding to SEK 0.02 per ordinary share. The warrants series TO 15 and TO 16 are issued free of charge.
One (1) warrant series TO 15 entitles the holder to subscription of one (1) ordinary share in the Company during the period from and including 8 January 2027 up to and including 22 January 2027.
One (1) warrant series TO 16 entitles the holder to subscription of one (1) ordinary share in the Company during the period from and including 7 January 2028 up to and including 21 January 2028.
Upon full subscription in the Rights Issue, Alligator Bioscience will initially receive approximately SEK 125.6 million before issue costs. In the event the warrants series TO 15 and TO 16 are fully exercised for subscription of new ordinary shares, at the same subscription price per ordinary share as in the Rights Issue, the Company will receive additional proceeds of approximately SEK 62.8 million in January 2027 and approximately SEK 62.8 million in January 2028, before issue costs.
The subscription period in the Rights Issue will run from and including 4 September 2026 up to and including 18 September 2026.
The Company intends to use the net proceeds from the Rights Issue, after repayment of the bridge loans, to refocus its operations on maintaining the future royalty upside from HLX22, fund the wind-down of its mitazalimab development activities, thereby providing funding to at least the topline data readout from the ongoing HLX22 Phase 3 trial, as well as for general corporate purposes and near-term strategic opportunities within mitazalimab.
The Rights Issue is covered by subscription undertakings up to approximately 2 percent and by guarantee commitments up to approximately 45 percent, corresponding to a total of approximately 47 percent of the Rights Issue.
For complete information on the Rights Issue, please see the published Prospectus.

The Prospectus
The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on 31 August 2026, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, is available on the Company’s website (www.alligatorbioscience.com) and APREA Partners’ website (www.apreapartners.com). The Prospectus will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se). Subscription forms will be available on the Company’s and APREA Partners’ respective websites.

Time plan for the Rights Issue

Last day of trading in shares including right to receive unit rights 31 August 2026
First day of trading in shares excluding right to receive unit rights 1 September 2026
Record date for the right to receive unit rights 2 September 2026
Trading in unit rights 4 – 15 September 2026
Subscription period 4 – 18 September 2026
Announcement of the outcome of the Rights Issue Around 22 September 2026
Trading in paid subscribed units (BTU) 4 September – 6 October 2026
Advisers
APREA Partners AB acts as financial adviser in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.

(Press release, Alligator Bioscience, AUG 31, 2026, View Source [SID1234670439])

On August 31, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported that the United States Patent and Trademark Office has granted a patent covering the use of the Company’s drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer. This newly issued U.S. patent expires December 20, 2039.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ampligen is a wide-spectrum Toll-like receptor 3 (TLR3) agonist, among other biological effects, and has been investigated for the treatment of various cancers, among other conditions. The Company has been issued multiple patents, and has filed multiple additional patent applications, directed to the use of Ampligen for cancer treatment.

"The issuance of this patent marks another significant step in building a broad and durable intellectual property patent estate around Ampligen’s potential role in cancer immunotherapy," said Thomas Equels, Chief Executive Officer of AIM ImmunoTech. "This patent protects Ampligen’s use in combination therapy with the leading PD-1 checkpoint therapy across a broad range of cancers and specifically encompasses pancreatic cancer, the central focus of our late-stage oncology strategy. Together with our existing U.S. and international patents covering Ampligen with PD-1 and PD-L1 checkpoint blockade, we believe this growing patent estate strengthens both the scientific and strategic foundation supporting Ampligen’s long-term oncology opportunity."

The newly issued patent’s broadest claim covers methods of treating cancer, by giving Ampligen together with pembrolizumab, whether administered at the same time or at different times, where the combination produces a greater effect against the cancer than either treatment alone, or than would be expected simply by adding their individual effects together. Other claims in the patent specifically name pancreatic cancer, skin cancer, colorectal cancer, ovarian cancer, melanoma, breast cancer, triple negative breast cancer, head and neck tumor, bladder cancer, renal cell carcinoma, and lung cancer as types of cancers for which the combination use is claimed in the patent, but the broad claim’s coverage is not limited to any cancer.

AIM also holds a U.S. patent, expiring August 9, 2039, covering methods of using Ampligen as part of a combination oncology therapy paired with an anti-programmed death-ligand 1 (PD-L1) antibody; a Netherlands patent, expiring December 19, 2039, broadly covering the use of Ampligen as a combination cancer therapy with PD-1 and PD-L1 checkpoint blockade inhibitors; and a Japanese patent, expiring December 20, 2039, covering the use of Ampligen in combination with either anti-PD-1 or anti-PD-L1 antibodies for the treatment of cancer.

(Press release, AIM ImmunoTech, AUG 31, 2026, View Source [SID1234670438])